Global Diagnostic Radioisotopes Market Size By Type (Tc99m, F-18), By Application (Oncology, Cardiology), By Region, And Segment Forecasts, 2023 to 2032

The Global Diagnostic Radioisotopes Market was valued at USD 5.6 billion in 2023 and is projected to reach USD 9.3 billion by 2031, growing at a CAGR of 6.6% during the forecast period from 2023 to 2031. The demand for diagnostic radioisotopes is being driven by the increasing prevalence of chronic diseases such as cancer and cardiovascular disorders, the rising adoption of nuclear medicine in imaging procedures, and technological advancements in radioisotope production. As healthcare systems continue to emphasize early and accurate diagnostics, nuclear imaging using radioisotopes is gaining prominence due to its superior sensitivity and specificity.

Drivers:

1. Growing Incidence of Chronic Diseases:

A rising number of cancer and cardiovascular disease cases globally is fueling the demand for precise diagnostic imaging techniques, where radioisotopes like technetium-99m play a vital role.

2. Technological Advancements in Imaging Modalities:

Improvements in hybrid imaging systems such as PET/CT and SPECT/CT are enhancing the utilization of diagnostic radioisotopes, boosting the market.

3. Expansion of Nuclear Medicine Infrastructure:

Global efforts to develop cyclotrons and establish local production facilities for radioisotopes are reducing reliance on imports and improving access, particularly in developing nations.

Restraints:

1. Short Half-Life of Radioisotopes:

Many diagnostic isotopes have short half-lives, requiring a robust and fast supply chain. This limitation complicates logistics and restricts widespread adoption.

2. Regulatory and Safety Concerns:

Stringent regulatory frameworks and radiation safety requirements increase the complexity and cost of handling radioisotopes, posing challenges to new market entrants.

Opportunity:

1. Rising Adoption in Emerging Markets:

Countries in Asia-Pacific and Latin America are investing heavily in healthcare infrastructure and nuclear medicine capabilities, creating strong growth opportunities.

2. Development of Novel Isotopes:

Innovations in radiopharmaceuticals and isotope labeling techniques are expanding the range of diseases that can be diagnosed, opening new application areas for radioisotopes.

Market by System Type Insights:

Based on system type, SPECT (Single Photon Emission Computed Tomography) dominated the market in 2023. SPECT is widely used for its cost-effectiveness, availability, and compatibility with key isotopes like technetium-99m. However, PET (Positron Emission Tomography) is anticipated to witness faster growth due to its superior resolution and increasing adoption in oncology diagnostics.

Market by End-use Insights:

Hospitals accounted for the largest revenue share in 2023, driven by the widespread availability of imaging infrastructure and growing patient footfall. Diagnostic imaging centers are expected to grow at a notable pace as outpatient services become more popular and accessible, especially in urban areas.

Market by Regional Insights:

North America held the largest market share in 2023, attributed to a mature nuclear medicine industry, strong reimbursement policies, and the presence of leading market players. Asia-Pacific is projected to exhibit the highest growth rate during the forecast period due to improving healthcare infrastructure, increased awareness, and regional isotope production initiatives in countries like India and China.

Competitive Scenario:

Key players in the Global Diagnostic Radioisotopes Market include:

Curium

GE Healthcare

Cardinal Health

Bracco Imaging

Lantheus Holdings, Inc.

Jubilant Radiopharma

NorthStar Medical Radioisotopes

Eckert & Ziegler

NTP Radioisotopes

Isotopia Molecular Imaging Ltd.

These companies are focusing on expanding production capacity, strategic collaborations, and R&D to develop next-generation radioisotopes and imaging agents.

Scope of Work – Global Diagnostic Radioisotopes Market

Key Market Developments:

2023: Curium launched a next-generation technetium generator system for faster preparation and enhanced radiation safety.

2024: GE Healthcare partnered with NorthStar Medical Radioisotopes to expand domestic Mo-99 production in the U.S.

2025: Lantheus Holdings received FDA approval for a novel PSMA-targeted PET imaging agent for prostate cancer diagnosis.

FAQs:

1) What is the current market size of the Global Diagnostic Radioisotopes Market?

The market size was USD 5.6 billion in 2023.

2) What is the major growth driver of the Global Diagnostic Radioisotopes Market?

The increasing prevalence of chronic diseases and advancements in nuclear imaging technologies.

3) Which is the largest region during the forecast period in the Global Diagnostic Radioisotopes Market?

North America is the largest regional market.

4) Which segment accounted for the largest market share in the Global Diagnostic Radioisotopes Market?

The SPECT system type segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Diagnostic Radioisotopes Market?

Key players include Curium, GE Healthcare, Lantheus Holdings, Cardinal Health, and Bracco Imaging.